A bill moving through Congress would speed government approval of lower-cost generic copies of brand-name drugs. But Endo Health Solutions reportedly is lobbying to require generic drugmakers to pay for independent tests to confirm their products are equivalent. "It could be a strategy in order to delay generic entry or make generics more costly," says George Chressanthis of Temple's Fox School of Business. "The other issue is to ensure that [generic drugs on the market are] truly bio-equivalent."